API

A steroid is a type of organic compound that contains...

read more...

Pharma Intermediate

Pharmaceuticals refer to the drugs and medicines...

read more...

Speciality Chemicals

Specialty chemicals are those chemicals which is produced...

read more...

Products Under Devp.

New Products Under Development In response...

read more...

AARTI DRUGS LIMITED

PART I
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER  ENDED 30th June, 2012
(Rs. In lakhs)
Sr. No. Particulars Quarter Ended Financial Year Ended
30th June 2012 31st Mar 2012 30th June 2011 31st Mar 2012
(Audited) (Audited) (Audited) (Audited)
1 Income from Operations
(a) Gross Sales / Income from Operations 20,396 21,165 15,689 69,918
Less : Excise Duty & Sales Tax 1,404 1,242 881 3,992
(a) Net Sales / Income from Operations 18,992 19,923 14,808 65,926
(Net Of Excise Duty & Sales Tax)
(b) Other Operating Income 3 590 4 610
Total income form operations (net) 18,995 20,513 14,812 66,536
2 Expenditure
(a).Cost of materials consumed 11,940 9,960 9,354 38,414
(b).Purchase of stock-in-trade 2,031 2,480 1,780 7,336
(c).Changes in inventories of finished goods, (1,012) 1,884 (812) (92)
work-in-progress and stock-in-trade
(d). Employee benefits expense 649 762 535 2,483
(e).  Depreciation and amortisation expense 632 629 492 2,422
(f). Other expenses 2,796 2,789 2,401 10,368
Total expenses 17,037 18,504 13,750 60,931
3 Profit from Operations before Other Income,
finance costs and exceptional items (1-2) 1,957 2,009 1,063 5,605
4 Other Income - -
5 Profit from ordinary activities before finance cost 1,957 2,009 1,063 5,605
and exceptional items (3+4)
6 Finance costs (interest) 651 697 400 2,267
7 Profit from ordinary activities after finance cost
but before Exceptional Items (5+6) 1,307 1,312 663 3,338
8 Exceptional Items 116 116
9 Profit from Ordinary Activities before Tax (7+8) 1,307 1,195 663 3,222
10 Tax Expenses  (Includes) 419 454 201 976
Provision for Taxation 355 390 163 800
Provision for Deferred Taxation 64 64 38 176
11 Net profit from ordinary Activities after Tax 888 741 462 2,246
13 Paid-up Equity Share Capital of  Rs.10/- each. 1,211 1,211 1,211 1,211
14 . Reserves & Surplus (excluding revaluation reserves) - 16,437
15.i Earning per share
(of rs /- each) (not annualised)
(a) Basic & Diluted 7.33 6.11 3.81 17.84

 

PART II
A PARTICULARS OF SHARHOLDING
1 Public shareholding
-Number of Shares 5,300,778 5,379,245 5,513,823 5,379,245
-Percentage of Total Shareholding 43.78 44.43 45.54 44.43
2 Promoters & Promoter Group shareholding
a) Pledged/Encumbered
- Number of Shares Nil Nil Nil Nil
-Percentage of shares( as a % of the Nil Nil Nil Nil
total shareholding of promoter and promoter group)
-Percentage of shares( as a % of the Nil Nil Nil Nil
total Share capital of the company)
b) Non-encumbered
- Number of Shares 6,807,772 6,729,305 6,594,727 6,729,305
-Percentage of shares( as a % of the total Shareholding 100 100 100 100
of promoter and promoter group)
-Percentage of shares( as a % of the total 56.22 55.57 54.46 55.57
Share capital of the company)
B INVESTOR COMPLAINTS Quarter Ended 30th June, 2012
Pending at the beginning of the quarter 0
Received during the quarter 1
Disposed of during the quarter 1
Remaining unresolved at the end of the quarter 0
Notes :
1 The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 10th August, 2012
2 Company is operating as a Single Segment Company, engaged in Pharmaceuticals Business.
3 Figures for the previous period have been regrouped or rearranged wherever necessary.
4 Previous year quarters (30th June-2011) figures are of Aarti Drugs Limited stand alone and hence are not comparable with the current year
For and on behalf of the Board
For AARTI DRUGS LIMITED
Place : Mumbai MR. HARSHIT M. SAVLA
Date: 10th August, 2012 (JT. MANAGING DIRECTOR)
 

Resource Download

Annual Report
Click here to download
annual report
Investor Presentation
Click here to download
Presentation

Copyright © 2010 Aarti Drugs Ltd. All Rights Reserved
Website Developed by : Sri Hema Infotech